Cargando…

MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is the most common kind of pediatric cancer. Although the cure rates in ALL have significantly increased in developed countries, still 15–20% of patients relapse, with even higher rates in developing countries. The role of non-coding RNA genes as microRNAs (miRNAs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendiola-Soto, Diana Karen, Bárcenas-López, Diego Alberto, Pérez-Amado, Carlos Jhovani, Cruz-Miranda, Gabriela Marisol, Mejía-Aranguré, Juan Manuel, Ramírez-Bello, Julian, Hidalgo-Miranda, Alfredo, Jiménez-Morales, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049736/
https://www.ncbi.nlm.nih.gov/pubmed/36982511
http://dx.doi.org/10.3390/ijms24065436
_version_ 1785014526090936320
author Mendiola-Soto, Diana Karen
Bárcenas-López, Diego Alberto
Pérez-Amado, Carlos Jhovani
Cruz-Miranda, Gabriela Marisol
Mejía-Aranguré, Juan Manuel
Ramírez-Bello, Julian
Hidalgo-Miranda, Alfredo
Jiménez-Morales, Silvia
author_facet Mendiola-Soto, Diana Karen
Bárcenas-López, Diego Alberto
Pérez-Amado, Carlos Jhovani
Cruz-Miranda, Gabriela Marisol
Mejía-Aranguré, Juan Manuel
Ramírez-Bello, Julian
Hidalgo-Miranda, Alfredo
Jiménez-Morales, Silvia
author_sort Mendiola-Soto, Diana Karen
collection PubMed
description Acute lymphoblastic leukemia (ALL) is the most common kind of pediatric cancer. Although the cure rates in ALL have significantly increased in developed countries, still 15–20% of patients relapse, with even higher rates in developing countries. The role of non-coding RNA genes as microRNAs (miRNAs) has gained interest from researchers in regard to improving our knowledge of the molecular mechanisms underlying ALL development, as well as identifying biomarkers with clinical relevance. Despite the wide heterogeneity reveled in miRNA studies in ALL, consistent findings give us confidence that miRNAs could be useful to discriminate between leukemia linages, immunophenotypes, molecular groups, high-risk-for-relapse groups, and poor/good responders to chemotherapy. For instance, miR-125b has been associated with prognosis and chemoresistance in ALL, miR-21 has an oncogenic role in lymphoid malignancies, and the miR-181 family can act either as a oncomiR or tumor suppressor in several hematological malignancies. However, few of these studies have explored the molecular interplay between miRNAs and their targeted genes. This review aims to state the different ways in which miRNAs could be involved in ALL and their clinical implications.
format Online
Article
Text
id pubmed-10049736
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100497362023-03-29 MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia Mendiola-Soto, Diana Karen Bárcenas-López, Diego Alberto Pérez-Amado, Carlos Jhovani Cruz-Miranda, Gabriela Marisol Mejía-Aranguré, Juan Manuel Ramírez-Bello, Julian Hidalgo-Miranda, Alfredo Jiménez-Morales, Silvia Int J Mol Sci Review Acute lymphoblastic leukemia (ALL) is the most common kind of pediatric cancer. Although the cure rates in ALL have significantly increased in developed countries, still 15–20% of patients relapse, with even higher rates in developing countries. The role of non-coding RNA genes as microRNAs (miRNAs) has gained interest from researchers in regard to improving our knowledge of the molecular mechanisms underlying ALL development, as well as identifying biomarkers with clinical relevance. Despite the wide heterogeneity reveled in miRNA studies in ALL, consistent findings give us confidence that miRNAs could be useful to discriminate between leukemia linages, immunophenotypes, molecular groups, high-risk-for-relapse groups, and poor/good responders to chemotherapy. For instance, miR-125b has been associated with prognosis and chemoresistance in ALL, miR-21 has an oncogenic role in lymphoid malignancies, and the miR-181 family can act either as a oncomiR or tumor suppressor in several hematological malignancies. However, few of these studies have explored the molecular interplay between miRNAs and their targeted genes. This review aims to state the different ways in which miRNAs could be involved in ALL and their clinical implications. MDPI 2023-03-12 /pmc/articles/PMC10049736/ /pubmed/36982511 http://dx.doi.org/10.3390/ijms24065436 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mendiola-Soto, Diana Karen
Bárcenas-López, Diego Alberto
Pérez-Amado, Carlos Jhovani
Cruz-Miranda, Gabriela Marisol
Mejía-Aranguré, Juan Manuel
Ramírez-Bello, Julian
Hidalgo-Miranda, Alfredo
Jiménez-Morales, Silvia
MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia
title MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia
title_full MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia
title_fullStr MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia
title_full_unstemmed MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia
title_short MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia
title_sort mirnas in hematopoiesis and acute lymphoblastic leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049736/
https://www.ncbi.nlm.nih.gov/pubmed/36982511
http://dx.doi.org/10.3390/ijms24065436
work_keys_str_mv AT mendiolasotodianakaren mirnasinhematopoiesisandacutelymphoblasticleukemia
AT barcenaslopezdiegoalberto mirnasinhematopoiesisandacutelymphoblasticleukemia
AT perezamadocarlosjhovani mirnasinhematopoiesisandacutelymphoblasticleukemia
AT cruzmirandagabrielamarisol mirnasinhematopoiesisandacutelymphoblasticleukemia
AT mejiaarangurejuanmanuel mirnasinhematopoiesisandacutelymphoblasticleukemia
AT ramirezbellojulian mirnasinhematopoiesisandacutelymphoblasticleukemia
AT hidalgomirandaalfredo mirnasinhematopoiesisandacutelymphoblasticleukemia
AT jimenezmoralessilvia mirnasinhematopoiesisandacutelymphoblasticleukemia